Compare Enact Holdings Inc (ACT) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Enact Holdings Inc vs Crispr Therapeutics AG — how do they compare? Enact Holdings Inc trades at $44.96 (market cap $6.35B), while Crispr Therapeutics AG trades at $59.25 (market cap $5.98B). The key difference: Enact Holdings Inc and Crispr Therapeutics AG are close in size by market cap, and Enact Holdings Inc pays a 1.91% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ACT | CRSP | |
|---|---|---|
Market Cap | $6.35B | $5.98B |
Sector | Technology | Health |
52-Week High | $45.71 | $76.78 |
52-Week Low | $34.39 | $44.34 |
Enterprise Value | $6.55B | $4.33B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
CRISPR Therapeutics (CRSP) trades at $60.77, up 1.15% with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company maintains strong cash reserves despite negative profitability metrics, with recent FDA approval for Casgevy pediatric use expanding its commercial potential. Technical indicators show the stock trading near pivot point resistance at $61 with RSI levels suggesting potential overbought conditions.
While CRSP shows promising growth potential with its pioneering gene-editing technology and recent regulatory wins, investors face significant risks from persistent negative margins and cash burn. The stock offers 19.6% upside to the consensus price target of $72.67, but requires careful monitoring of commercialization progress and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
